Therapy with 2′-O-Me Phosphorothioate Antisense Oligonucleotides Causes Reversible Proteinuria by Inhibiting Renal Protein Reabsorption-Reference-Cited by-同舟云学术

Therapy with 2′-O-Me Phosphorothioate Antisense Oligonucleotides Causes Reversible Proteinuria by Inhibiting Renal Protein Reabsorption

Published:2019-12 Issue: Volume:18 Page:298-307
ISSN:2162-2531
Container-title:Molecular Therapy - Nucleic Acids
language:en
Short-container-title:Molecular Therapy - Nucleic Acids

Author:

Janssen Manoe J.,Nieskens Tom T.G.,Steevels Tessa A.M.,Caetano-Pinto Pedro,den Braanker Dirk,Mulder Melissa,Ponstein Yolanda,Jones Shaun,Masereeuw Rosalinde,den Besten Cathaline,Wilmer Martijn J.

Funder

BioMarin

Publisher

Elsevier BV

Subject

Drug Discovery,Molecular Medicine

Reference47 articles.

1. Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma;Herrington;Am. J. Kidney Dis.,2011

2. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study;Voit;Lancet Neurol.,2014

3. Renal uptake and tolerability of a 2′-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey;Henry;Toxicology,2012

4. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides;Geary;Adv. Drug Deliv. Rev.,2015

5. The delivery of therapeutic oligonucleotides;Juliano;Nucleic Acids Res.,2016

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using RNA-based therapies to target the kidney in cardiovascular disease;Frontiers in Cardiovascular Medicine;2023-10-06

2. RNAi therapies: Expanding applications for extrahepatic diseases and overcoming delivery challenges;Advanced Drug Delivery Reviews;2023-10

3. Focal Segmental Glomerulosclerosis Complicating Therapy With Inotersen, an Antisense Oligonucleotide Inhibitor: A Case Report;American Journal of Kidney Diseases;2023-05

4. A Brief Review of Duchenne Muscular Dystrophy Treatment Options, with an Emphasis on Two Novel Strategies;Biomedicines;2023-03-09

5. Epidermal growth factor receptor mediates the basolateral uptake of phosphorothioate-modified antisense oligonucleotides in the kidney;Organs-on-a-Chip;2022-12